RAP 0.00% 20.5¢ resapp health limited

The reason that Pfizer want this tech is as...

  1. 71 Posts.
    lightbulb Created with Sketch. 278
    The reason that Pfizer want this tech is as follows:

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

    latest news May 2022;

    Paxlovid is the latest COVID-19 treatment that’s been all over the news. The drug was granted an emergency use authorization (EUA) by the Food and Drug Administration (FDA) in December for anyone ages 12 and older who weighs at least 88 pounds, and is at high risk for severe disease. Pfizer recently began Phase 2 and 3 trials in children and teens ages 6 to 17.

    Paxlovid is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized. So, if you test positive for the coronavirus and a health care provider writes you a prescription, you can take pills at home and lower your risk of going to the hospital.

    The drug, developed by Pfizer, has a lot of positives: It had an 89% reduction in the risk of hospitalization and death in the clinical trial that supported the EUA, a number that was high enough to prompt the National Institutes of Health (NIH) to prioritize it over other COVID-19 treatments; it’s cheaper than many other COVID-19 drugs (it’s provided for free by the U.S. government while there is a public health emergency); and, perhaps most reassuring, it is expected to work against the Omicron variant.

    “I think it is the beginning of a ‘game-changer,’” says Scott Roberts, MD, a Yale Medicine infectious diseases specialist. “It's really our first efficacious oral antiviral pill for this virus. It shows clear benefit, and it really can prevent hospitalization and death in people who are at high risk.”

    Resapp have already surveyed its shareholders and I bet most of them said they wont sell for 11.5cents. We'll have to wait for the independent valuation - but hopefully has come in significantly higher and Pfizer will have to up their bid.
    As Redbar has said - other big tech has also been sniffing around waiting for this valuation and we may see other players put in a bid or two - that would be nice.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.